Browsing by Subject "Fascin"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Fascin in ovarian epithelial tumors
    (Murcia : F. Hernández, 2008) Kostopoulou, Evanthia; Daponte, Alexandros; Terzis, Anastasios; Nakou, María; Chiotoglou, Ioanna; Theodosiou, Dimitrios; Chatzichristodoulou, Christos; Messinis, Ioannis E.; Koukoulis, George
    Fascin contributes to the formation of actinbased protrusions involved in cell migration. Fascin has emerged as a prognostic marker in some carcinomas. We examined ovarian neoplasms to check any correlation between fascin expression and established clinicopathologic parameters. Fascin immunoreactivity was semiquantitavely scored in 100 ovarian tumors (62 carcinomas, 15 borderline tumors and 23 cystadenomas). Double staining for fascin and Ki-67 was performed in selected carcinomas. Western Blotting was done in frozen samples. Fascin immunoreactivity was highest in carcinomas, lowest in cystadenomas and intermediate in borderline tumors; these results were in accordance with those from Western blotting analysis. Fascin was statistically increased in carcinomas of advanced stage and in serous carcinomas. It was also increased in metastatic foci and in tumor foci with lower Ki-67 labeling. We conclude that in ovarian tumors fascin is associated with certain features of increased tumor aggressiveness. Future studies could determine if fascin may become a routinely helpful marker in gynecological pathology or clinical oncology.
  • Thumbnail Image
    Publication
    Open Access
    Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness
    (Murcia : F. Hernández, 2006) Jin, J.S.; Yu, C.P.; Sun, G.H.; Lin, Y.F.; Chiang, H.; Chao, T.K.; Tsai, W.C.; Sheu, L.F.
    Aim: To determine whether higher expression of fascin, an actin-bundling protein associated with motility, in conventional renal cell carcinoma (RCC) is associated with more advanced stages of the disease. Methods: Immunohistochemical analysis of fascin expression was performed in tissue microarrays of 108 RCCs including 55 clear cell RCCs (CRCCs), 39 CRCCs with granular cell differentiation (GRCCs), 8 CRCCs with sarcomatoid differentiation (SRCCs) and 6 metastatic RCCs. Results: The expression of fascin was undetectable in normal renal tubules of all control cases. However, among the 108 RCC cases, fascin immunoreactivity was seen on the cell membrane and cytoplasm. The average immunostaining score for fascin was 128/400 in grade I, 170/400 in grade II, 207/400 in grade III, and 323/400 in grade IV RCC. The average immunostaining score of fascin was 187/400 for stage T1, 205/400 for stage T2, 288/400 for stage T3, and 355/400 for stage T4 cases of RCCs. Higher fascin scores in RCC were significantly correlated with higher T and N stages and nuclear grade. In addition, the fascin scores in GRCC (368±19) and SRCC (263±21) were significantly higher than in CRCC 95±18). Conclusions: Our findings demonstrate for the first time that increased expression of fascin is associated with clinicopathological parameters of aggressiveness in patients with RCC. Fascin may be a novel biomarker for diagnosis and treatment of RCC.